Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (2025)
9 slides from Bayer's technical presentation, 2025
Slide 1: Effects of Finerenone on Heart Failure Outcomes According to Baseline HF Risk in CKD and T2D
Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes John W. Ostrominski, MD; Brendon L. Neuen, MBBS MSc PhD; Brian L. Claggett, PhD; Rajiv Agarwal, MD; Stefan D. Anker, MD PhD; Gerasimos Filippatos, MD; Peter Rossing,
Slide 2: Financial Disclosure
FINANCIAL DISCLOSURE • JWO reports research grant support from the National Institutes of Health (5T32HL007604-39 and L30HL175757) and has served on advisory boards or had speaker engagements with Corcept Therapeutics • The FIDELIO-DKD and FIGARO-DKD trials were sponsored by Bayer AG
Slide 3: Background
BACKGROUND • Persons with CKD and type 2 diabetes HF Hospitalization in FIDELITY (T2D) experience substantial, but often underappreciated, risks of HF events • As such, therapeutic strategies that reduce the HF risks in this population are important • Finerenone has been shown to reduce HF hospitali
Slide 4: FIDELITY Objective and Study Population
OBJECTIVE AND STUDY POPULATION In this secondary analysis of the FIDELITY program, we evaluated the relative and absolute effects of finerenone on HF outcomes according to baseline HF risk FIDELITY n=12,990 • Recruitment: 2015-2018 • Recruitment: 2015-2018 • Population: CKD and T2D, with • Populatio
Slide 5: Methods
METHODS • Exposure: HF risk – Based on the validated Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM) • TRS-HFDM = history of HF (2 points) + history of atrial fibrillation (1 point) + history of CAD (1 point) + eGFR <60 mL/min/1.73 m2 (1 point) + UACR 30-300
Slide 6: Distribution of HF Risk in FIDELITY
DISTRIBUTION OF HF RISK IN FIDELITY Distribution of Baseline HF Risk in Incidence of CV Death or HF FIDELITY Hospitalization, by Baseline HF Risk Most (58%) FIDELITY participants had a high or very high predicted risk of HF events; baseline TRS-HFDM score was incrementally associated with CV events
Slide 7: Relative Effects of Finerenone, by Baseline HF Risk
RELATIVE EFFECTS OF FINERENONE, BY BASELINE HF RISK Treatment effects of finerenone vs. placebo on key cardiovascular outcomes, overall and by TRS-HFDM risk category, estimated through Cox proportional hazards regression, stratified by trial and the trial-specific stratification factors
Slide 8: Absolute Benefits of Finerenone, by Baseline HF Risk
ABSOLUTE BENEFITS OF FINERENONE, BY BASELINE HF RISK Absolute treatment effects of finerenone versus placebo on key cardiovascular outcomes, by TRS-HFDM risk category. Absolute risk differences per 1,000 persons were estimated through Poisson regression.
Slide 9: Discussion and Conclusions
DISCUSSION AND CONCLUSIONS • Higher baseline TRS-HFDM scores were associated with an incrementally higher rate of adverse cardiovascular outcomes in FIDELITY • Relative benefits of finerenone on CV death or HF hospitalization were consistent, irrespective of baseline TRS-HFDM score • Due to higher b